Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card
12:11pm, Friday, 13'th Dec 2024
Incumbent Board has Destroyed Stockholder Value and Imperiled AIM's Future through Breaches of Fiduciary Duty and Bad Faith Actions
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card
09:46am, Friday, 13'th Dec 2024
Vote “ FOR ” All Four Kellner Group Nominees for Urgently Needed Change
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
03:00pm, Thursday, 12'th Dec 2024
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stoc
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland)
Kellner Group Announces Support from Another Former AIM Senior Executive
08:16am, Thursday, 12'th Dec 2024
NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectivel
Eden Research's regulatory wins keep coming at breakneck pace
09:22am, Wednesday, 11'th Dec 2024
Today's announcement that AIM-listed biopesticides developer Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)'s flagship fungicide product Mevalone has been added to the Organic Input List in Germany didn't
AIM's Clinical Strategy Under Incumbent Board Has Totally Failed
07:30am, Wednesday, 11'th Dec 2024
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectivel
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.
10:20am, Tuesday, 10'th Dec 2024
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”)
Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected
07:30am, Tuesday, 10'th Dec 2024
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE)
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
09:15am, Friday, 06'th Dec 2024
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
08:34am, Friday, 06'th Dec 2024
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency According to ISS – “ There is no question that for shareholders to have any hope of not losing 1
SDX Energy shares plunge on London delisting plan
04:23am, Friday, 06'th Dec 2024
SDX Energy PLC (AIM:SDX, OTC:SDXEF) shares plunged around 60% in value on Friday as it announced it intends to exit the London Stock Exchange, delisting from AIM to take up private company status. It
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.
09:00am, Thursday, 05'th Dec 2024
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Institutional Shareholder Services Inc. (�
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
07:30am, Monday, 02'nd Dec 2024
Kellner Group Has Financial Resources AIM Needs Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders AIM Cash Conservation Plan is Too Little Too Late, Exposes Despera
AIM ImmunoTech Refutes Activist Group's False and Misleading Claims
03:30pm, Wednesday, 27'th Nov 2024
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement refuting the false and misleading claims recently made by a
